

Glenmark – Recall of naproxen tablets

• On April 25, 2022, <u>Glenmark announced</u> a consumer-level recall of two lots of <u>naproxen</u> tablets due to gaps in the microbiology quality control system.

Product Description	NDC#	Lot# (Expiration Date)
Naproxen 275 mg tablets	68462-178-01	29200077 (11/30/2022); 29200078 (11/30/2022)

- Naproxen tablets are indicated for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendonitis, bursitis, acute gout; and for the management of pain and primary dysmenorrhea.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Patients should contact their physician or health care provider if they have experienced any problems that may be related to taking or using the recalled naproxen.
- Contact Qualanex by phone at **1-888-504-2012** or by email at <u>recall@qualanex.com</u> for return information and for more information about the recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.